Status:
UNKNOWN
Value of KL-6 in Rheumatoid Arthritis-Associated ILD
Lead Sponsor:
Assiut University
Conditions:
Rheumatoid Arthritis-Associated Interstitial Lung Disease
Eligibility:
All Genders
18-80 years
Brief Summary
Evaluation of serum KL6 level in rheumatoid arthritis-associated interstitial lung disease (RA-ILD).
Detailed Description
Rheumatoid arthritis (RA) is one of the most common connective tissue diseases (CTD). Its prevalence is increasing worldwide . It is responsible for a considerable number of hospital visits in Egyptia...
Eligibility Criteria
Inclusion
- Diagnosis of RA will be based on American College of Rheumatology/European League against Rheumatism (ACR-EULAR) classification criteria 2010.
- all patients have rheumatoid arthritis-associated interstitial lung disease
Exclusion
- Patients with any evidence of infection will be excluded.
Key Trial Info
Start Date :
January 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT05979454
Start Date
January 1 2023
End Date
December 1 2023
Last Update
November 2 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Safaa A Eid
Asyut, Egypt